^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KRLS-017

    i
    Other names: KRLS-017, UD017, UD 017, UD-017
    Company:
    Kirilys, Ube Corp
    Drug class:
    CDK7 inhibitor
    Related drugs:
    26d
    Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis. (PubMed, Mol Cancer Ther)
    An enhancement in inhibition of tumor growth and suppression of c-MYC expression was further confirmed when enzalutamide combined with KRLS-017 in an MDA-MB-453 mouse model. Our study suggests that KRLS-017 enhances the antitumor efficacy of enzalutamide by inhibiting c-MYC-mediated tumorigenesis and presents a potential new approach for treating AR+ LAR TNBC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AR (Androgen receptor) • CDK7 (Cyclin Dependent Kinase 7)
    |
    AR positive • MYC expression • AR expression
    |
    Xtandi (enzalutamide) • KRLS-017
    2years
    Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer (SABCS 2022)
    Our results suggest that enzalutamide synergizes with UD-017 by inhibiting c- MYC–mediated oncogenic activity. These in vitro data warrant future in vivo studies of the antitumor synergy of enzalutamide plus UD-017 in AR+ LAR TNBC models.
    Clinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AR (Androgen receptor) • CDK7 (Cyclin Dependent Kinase 7)
    |
    AR positive • MYC overexpression • MYC expression • AR expression
    |
    Xtandi (enzalutamide) • KRLS-017